AR101715A1 - Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis - Google Patents

Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis

Info

Publication number
AR101715A1
AR101715A1 ARP150102764A ARP150102764A AR101715A1 AR 101715 A1 AR101715 A1 AR 101715A1 AR P150102764 A ARP150102764 A AR P150102764A AR P150102764 A ARP150102764 A AR P150102764A AR 101715 A1 AR101715 A1 AR 101715A1
Authority
AR
Argentina
Prior art keywords
mycobacterium tuberculosis
seq
peptides
diagnosticate
latent infection
Prior art date
Application number
ARP150102764A
Other languages
English (en)
Original Assignee
Centre Nat De La Rech Scient (Cnrs)
Consejo Nac De Investig Científicas Y Técnicas (Conicet)
Inst Jean Paoli & Irene Calmettes
Université Daix-Marseille
Inst Nat De La Sante Et De La Rech Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat De La Rech Scient (Cnrs), Consejo Nac De Investig Científicas Y Técnicas (Conicet), Inst Jean Paoli & Irene Calmettes, Université Daix-Marseille, Inst Nat De La Sante Et De La Rech Medicale (Inserm) filed Critical Centre Nat De La Rech Scient (Cnrs)
Publication of AR101715A1 publication Critical patent/AR101715A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente solicitud se relaciona con una composición que comprende por lo menos tres péptidos derivados del antígeno de Mycobacterium tuberculosis Rv2626c, su uso en el diagnóstico de sujetos con infección latente por Mycobacterium tuberculosis (o LTBI, Latent TB infection), los correspondientes métodos de uso y kits. Reivindicación 1: Una composición que comprende por lo menos tres péptidos, en la cual las secuencias de aminoácidos de dichos por lo menos tres péptidos comprenden fragmentos distintivos que tienen de 5 a 30 aminoácidos contiguos de la secuencia de aminoácidos del antígeno de Mycobacterium tuberculosis Rv2626c de SEC ID Nº 1, y quedan excluidos los péptidos de la secuencia de aminoácidos de SEC ID Nº 40, SEC ID Nº 41 y SEC ID Nº 42.
ARP150102764A 2014-08-29 2015-08-28 Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis AR101715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306329 2014-08-29

Publications (1)

Publication Number Publication Date
AR101715A1 true AR101715A1 (es) 2017-01-11

Family

ID=51535398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102764A AR101715A1 (es) 2014-08-29 2015-08-28 Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis

Country Status (6)

Country Link
US (2) US10067147B2 (es)
EP (1) EP3194969B1 (es)
CN (1) CN107076744B (es)
AR (1) AR101715A1 (es)
WO (1) WO2016030526A1 (es)
ZA (1) ZA201701217B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030526A1 (en) * 2014-08-29 2016-03-03 Centre National De La Recherche Scientifique (C.N.R.S) Compositions useful in the diagnostic of latently infected mycobacterium tuberculosis
CN106405113A (zh) * 2016-09-13 2017-02-15 深圳市达科为生物工程有限公司 一种用于检测潜在结核的特异性标志物及其应用
US20190162725A1 (en) * 2017-11-29 2019-05-30 Mitch Magee Materials and methods relating to antibody targets for tuberculosis serology
AU2019260805A1 (en) * 2018-04-26 2020-11-26 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN113980145B (zh) * 2021-11-08 2022-08-12 成都可恩生物科技有限公司 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN114907460B (zh) * 2022-05-24 2023-12-22 中国人民解放军总医院第八医学中心 结核分枝杆菌LTBI-RD相关蛋白抗原Th1表位肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030368D0 (en) * 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
CN101203239B (zh) * 2005-03-31 2014-09-17 莱顿大学医药中心 诊断、预防和治疗分枝杆菌感染和结核疾病的方法和装置
US7993657B2 (en) * 2005-07-26 2011-08-09 University Of Medicine And Dentistry Of New Jersey Antibody profiles characteristic of tuberculosis state
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
WO2014059336A1 (en) * 2012-10-12 2014-04-17 University Of Notre Dame Du Lac Exosomes and diagnostic biomarkers
CN103360480A (zh) * 2013-08-02 2013-10-23 扬州大学 一种结核蛋白及其制备和应用
WO2016030526A1 (en) * 2014-08-29 2016-03-03 Centre National De La Recherche Scientifique (C.N.R.S) Compositions useful in the diagnostic of latently infected mycobacterium tuberculosis

Also Published As

Publication number Publication date
US20170242038A1 (en) 2017-08-24
US20180328948A1 (en) 2018-11-15
US10067147B2 (en) 2018-09-04
EP3194969B1 (en) 2023-06-07
US11448656B2 (en) 2022-09-20
CN107076744B (zh) 2021-01-19
CN107076744A (zh) 2017-08-18
EP3194969A1 (en) 2017-07-26
ZA201701217B (en) 2019-06-26
WO2016030526A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
AR101715A1 (es) Composiciones útiles para diagnosticar infección latente por mycobacterium tuberculosis
AR105470A1 (es) Métodos para inducir una respuesta inmune
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
BR112017003582A2 (pt) anticorpos, composições e usos
AR101669A1 (es) Constructos de anticuerpos para cdh19 y cd3
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
BR112018014238A2 (pt) composição e métodos para criopreservação de hutc
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112016016103A2 (pt) Composição de antígenos micobacterianos
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
BR112016030294A2 (pt) Cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas
CO2017007338A2 (es) Composición que comprende dos cepas de las especies microbianas lactobacillus rhamnosus y bifidobacterium longum capaces de incrementar la fertilidad masculina
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
AR109799A1 (es) Composición para el tratamiento del cabello
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas